It is now well established that routine screening for ovarian cancer in average-risk women utilizing transvaginal ultrasound, cancer antigen 125 (CA-125) testing, or their combination has no significant effect on ovarian cancer mortality [38], and thus is not recommended by the US Preventive Services Task Force (USPSTF) [39], which based their conclusion on the four largest studies including the Prostate, Lung, Colorectal and Ovarian screening trial (PLCO) [40, 41] and the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) [42]. Here, MUC16 is linked to ovarian carcinoma.